Low-dose chemotherapy and rituximab for post-transplant lymphoproliferative disease (PTLD): A Children's Oncology Group report

Optimal therapy for post-transplant lymphoproliferative disease (PTLD) remains problematic. A phase II trial adding rituximab to a low-dose cyclophosphamide and prednisone regimen was conducted for pediatric patients with Epstein-Barr virus (EBV) (+), CD20 (+) PTLD. Fifty-five patients were enrolled...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gross, Thomas G., Orjuela, Manuela A., Perkins, Sherrie L., Park, Julie R., Lynch, James C., Cairo, Mitchell S., Smith, Lynette M., Hayashi, Robert J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3484187/
https://ncbi.nlm.nih.gov/pubmed/22883417
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1600-6143.2012.04206.x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados